University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
NCT Number: NCT00611312
The purpose of this study is to see if an intense two-week long cognitive training program helps the thinking ability of adults with very mild Alzheimer Disease. We anticipate that scores on clinical cognitive tests will be better after the training.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Phase 2
Kansas City, Kansas, 66160, United States
Twenty of the 30 subjects will be recruited to participate in functional magnetic resonance imaging (fMRI). Scanning will be done while subjects perform a verbal learning task. Ten subjects will be scanned before and after the two week training. Another ten will be scanned twice at a two week interval before beginning the cognitive training.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
Time frame: 2 weeks with FU at 2 and 4 months
Time frame: 2 weeks
University of Kansas
Other
Effects of Intense Cognitive Training on Standardized Measures of Cognition in Those With Very Mild Alzheimer's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05519137
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04867616
Alzheimer Disease, Alzheimer's Disease
Fresno, California, United States
View Trial DetailsNCT02947893
Alzheimer Disease, Alzheimer's Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details